Company: BNBX
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001104659-25-105958
Chunk: 24

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 424B5
Chunk 24
---
 of the State of Florida as Datalink Systems, Inc. In 1998, we reincorporated in the State of Nevada,
and in 2002, we changed our name to our current name, Applied DNA Sciences, Inc. On December 17, 2008, we reincorporated from
the State of Nevada to the State of Delaware.

Our corporate headquarters are located at the
Long Island High Technology Incubator at Stony Brook University in Stony Brook, New York, where we have established laboratories for the
manufacture and development of our nucleic acid production solutions. The mailing address of our corporate headquarters is 50 Health Sciences
Drive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800.

| S-13 |

<div align='center'>THE OFFERING</div>

| Common Stock Offered by Us                   | Shares of our common stock having an aggregate offering price of up to $8,157,932.                                                                                                                                                                                                                                                            |
| Common Stock Outstanding After This Offering | Up to 6,719,400 shares, assuming the sale of up to 2,364,618 shares of our common stock at a price of $3.45 per share, which was the closing price of our common stock on Nasdaq on October 31, 2025. The actual number of shares issued will vary depending on the sales price under this offering.                                          |
| Plan of Distribution                         | “At the market offering” that may be made from time to time through our sales agent, Lucid. See “Plan of Distribution” on page S-25.                                                                                                                                                                                                          |
| Use of Proceeds                              | We intend to use the net proceeds from this offering primarily for the continued development and implementation of our BNB Strategy.as well as for working capital and general corporate purposes. See “Use of Proceeds” on page S-24.                                                                                                        |
| Risk Factors                                 | You should read the “Summary of Risk Factors” and “Risk Factors” sections of this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference in this prospectus supplement and accompanying prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock. |
| Symbol on Nasdaq                             | “BNBX”                                                                                                                                                                                                                                                                                                                                        |

The number of shares of common stock to be outstanding
immediately after this offering is based on 4,354,782 shares of common stock outstanding as of October 31,